What Makes Cassava Sciences (SAVA) a New Buy Stock - Yahoo …
1 day ago · Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal …
Nov 6, 2024 · Cassava Sciences is nearing a Phase 3 readout for its Alzheimer's drug, lecanemab, despite facing a scandal involving the SEC. Learn more about the latest updates on donanemab and the company's ...
Cassava Sciences Reports Q3 2024 Financial and Operating Results
In This Article: $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026. AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc ...
Cassava Sciences: Pivotal Alzheimer’s Data May Push Stock …
6 days ago · Cassava Sciences expects to release top-line data from the RETHINK-ALZ Phase 3 trial by year-end 2024. The RETHINK-ALZ trial enrolled 804 patients, with over 635 completing the 52-week study.
PRESS RELEASES | Cassava Sciences, Inc.
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials. An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials.
Cassava Sciences Resolves SEC Investigation
Sep 26, 2024 · Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented remedial measures.
Cassava Sciences Reports Q3 2024 Financial and Operating Results
Sep 30, 2024 · AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today reported financial results for the third quarter ended September 30, 2024. “We look forward to the release of top-line results from RETHINK-ALZ ...
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
Jul 18, 2024 · Two top officials at Cassava Sciences — a small pharmaceutical company in Austin, Texas, embroiled in years of controversy over a proposed Alzheimer’s drug — have resigned.
Cassava Sciences Announces Positive Top-Line Clinical Results in …
AUSTIN, Texas, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug...
After Cassava Alzheimer drug fiasco, FDA must protect patients
Oct 2, 2024 · For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s...
- Some results have been removed